All In Biotech

Drug Trial Radar · NCT06862791

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight With Co-morbidity (ASCEND)

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 377 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

377

Actual

Start

Feb 18, 2025

Primary completion

May 11, 2026

Study completion May 11, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.

Conditions

  • Obesity or Overweight

Interventions

  • AZD9550Drug

    IMP injected subcutaneous, once weekly. Unit dose strength as per CSP

  • AZD6234Drug

    IMP injected subcutaneous, once weekly. Unit dose strength as per CSP.

  • Placebo comparatorDrug

    Placebo matching IMP dose injected subcutaneously, once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight from baseline after 36 weeks of treatmentTime frame: 36 weeks
  2. Weight loss ≥ 5% from baseline after 36 weeks of treatmentTime frame: 36 weeks

Locations

53 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Dothan, Alabama

  • Research Site

    Vestavia Hills, Alabama

  • Research Site

    Cerritos, California

  • Research Site

    Escondido, California

  • Research Site

    Huntington Park, California

  • Research Site

    Lincoln, California

  • Research Site

    Sacramento, California

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Palm Harbor, Florida

  • Research Site

    Decatur, Georgia

  • Research Site

    Stockbridge, Georgia

  • Research Site

    Champaign, Illinois

  • Research Site

    South Bend, Indiana

  • Research Site

    Valparaiso, Indiana

  • Research Site

    Sioux City, Iowa

  • Research Site

    Southfield, Michigan

  • Research Site

    Missoula, Montana

  • Research Site

    Omaha, Nebraska

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Fargo, North Dakota

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Medford, Oregon

  • Research Site

    Kingsport, Tennessee

  • Research Site

    Brownsville, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Arlington, Virginia

  • Research Site

    Renton, Washington

  • Research Site

    Maroochydore, Australia

  • Research Site

    Maroubra, Australia

  • Research Site

    Norwood, Australia

  • Research Site

    St Albans, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Surrey, British Columbia, Canada

  • Research Site

    Guelph, Ontario, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    Sarnia, Ontario, Canada

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.